Antibodies, Neoplasm

• 

  Subject Areas on Research

  • A comparison of alemtuzumab with basiliximab induction in simultaneous pancreas-kidney transplantation. 
  • A preliminary study utilizing viable HLA mismatched cultured glioma cells as adjuvant therapy for patients with malignant gliomas. 
  • Abundant tyrosine residues in the antigen binding site in anti-osteosarcoma monoclonal antibodies TP-1 and TP-3: Application to radiolabeling. 
  • Activated α2-macroglobulin binding to human prostate cancer cells triggers insulin-like responses. 
  • Acute lymphoblastic leukemia: classification and characterization with antisera to human T-cell and Ia antigens. 
  • Alemtuzumab for the prevention and treatment of graft-versus-host disease. 
  • Alemtuzumab in relapsed or refractory chronic lymphocytic leukemia and prolymphocytic leukemia. 
  • Alemtuzumab in the treatment of refractory acute rejection and bronchiolitis obliterans syndrome after human lung transplantation. 
  • Alemtuzumab induction and antibody-mediated kidney rejection after simultaneous pancreas-kidney transplantation. 
  • Alemtuzumab induction and recurrence of glomerular disease after kidney transplantation. 
  • Alemtuzumab induction and triple maintenance immunotherapy in kidney transplantation from donors after cardiac death. 
  • Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. 
  • Alemtuzumab. 
  • Aneuploid subpopulations in tumour-invaded lymph nodes from breast cancer patients. 
  • Antibody against T lymphoblastic leukemia-associated antigen (3-40) identifies vimentin and keratin intermediate filaments in normal cells. 
  • Antibody-based biosensor for breast cancer with ultrasonic regeneration. 
  • Antibody-conjugated gold-gold sulfide nanoparticles as multifunctional agents for imaging and therapy of breast cancer. 
  • Antibody-dependent cellular cytotoxicity and disease course in North American patients with nasopharyngeal carcinoma: a prospective study. 
  • Antigens shared by rat schwannomas, neuroblastomas, and a testicular interstitial cell carcinoma. 
  • Application of Bayesian modeling of autologous antibody responses against ovarian tumor-associated antigens to cancer detection. 
  • Aspects of immunobiology and immunotherapy and uses of monoclonal antibodies and biologic immune modifiers in human gliomas. 
  • Autoantibody biomarkers identified by proteomics methods distinguish ovarian cancer from non-ovarian cancer with various CA-125 levels. 
  • Autoimmune thyroid disease after renal transplantation using depletional induction with alemtuzumab. 
  • BAFF is increased in renal transplant patients following treatment with alemtuzumab. 
  • Bilateral vocal cord paresis as a presenting sign of paraneoplastic syndrome: case report. 
  • Binding of anti-GRP78 autoantibodies to cell surface GRP78 increases tissue factor procoagulant activity via the release of calcium from endoplasmic reticulum stores. 
  • Brief communication: melanoma-specific antibodies produced in monkeys by immunization with human melanoma cell lines. 
  • CALGB 150905 (Alliance): rituximab broadens the antilymphoma response by activating unlicensed NK cells. 
  • CAMPATH-1H in rheumatoid arthritis--an intravenous dose-ranging study. 
  • CD4+ CD25+ FOXP3+ regulatory T cells increase de novo in kidney transplant patients after immunodepletion with Campath-1H. 
  • CDX-1307: a novel vaccine under study as treatment for muscle-invasive bladder cancer. 
  • Calcineurin inhibitor withdrawal after renal transplantation with alemtuzumab: clinical outcomes and effect on T-regulatory cells. 
  • Campath-1H in intestinal and multivisceral transplantation: preliminary data. 
  • Campath-1H in renal transplantation: The University of Wisconsin experience. 
  • Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study. 
  • Campath-1H use in pediatric renal transplantation. 
  • Carbohydrate recognition on MUC1-expressing targets enhances cytotoxicity of a T cell subpopulation. 
  • Cell binding and tumor inhibiting functions of a new antihuman melanoma murine monoclonal antibody. 
  • Cell surface reactive human monoclonal antibody directed to human melanoma-associated gangliosides. 
  • Characterization of prostate-tissue-directed monoclonal antibody, alpha-Pro 13. 
  • Co-delivery of antigen and IL-12 by Venezuelan equine encephalitis virus replicon particles enhances antigen-specific immune responses and antitumor effects. 
  • Coexpression of the HER-2 gene product, p185HER-2, and epidermal growth factor receptor, p170EGF-R, on epithelial ovarian cancers and normal tissues. 
  • Correlation between human leukocyte antigen antibody production and serum creatinine in patients receiving sirolimus monotherapy after Campath-1H induction. 
  • Cyclosporine inhibition of a murine B cell lymphoma. 
  • Dendritic cell recovery following nonmyeloablative allogeneic stem cell transplants. 
  • Detection of humoral response in patients with glioblastoma receiving EGFRvIII-KLH vaccines. 
  • Development and characterization of a monoclonal antibody to human embryonal carcinoma. 
  • Dissociation of depletional induction and posttransplant lymphoproliferative disease in kidney recipients treated with alemtuzumab. 
  • EGFRvIII as a promising target for antibody-based brain tumor therapy. 
  • Early and limited use of tacrolimus to avoid rejection in an alemtuzumab and sirolimus regimen for kidney transplantation: clinical results and immune monitoring. 
  • Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis. 
  • Enhanced tumour uptake of radiolabelled antibodies by hyperthermia. Part II: Application of the thermal equivalency equation. 
  • Enhanced tumour uptake of radiolabelled antibodies by hyperthermia: Part I: Timing of injection relative to hyperthermia. 
  • Expression of major histocompatibility complex class I antigens in normal and transformed rat thyroid epithelial cell lines. 
  • FOXP3 expression following bone marrow transplantation for IPEX syndrome after reduced-intensity conditioning. 
  • Finding the right job for the tool: alemtuzumab and its role in renal transplantation. 
  • Five new epitope-defined monoclonal antibodies reactive with GM2 and human glioma and medulloblastoma cell lines. 
  • Fludarabine followed by alemtuzumab consolidation for previously untreated chronic lymphocytic leukemia: final report of Cancer and Leukemia Group B study 19901. 
  • How does alemtuzumab affect long-term graft and patient outcomes after deceased-donor kidney transplantation? 
  • IGHV1-69 B cell chronic lymphocytic leukemia antibodies cross-react with HIV-1 and hepatitis C virus antigens as well as intestinal commensal bacteria. 
  • Identifying alemtuzumab as an anti-myeloid cell antiangiogenic therapy for the treatment of ovarian cancer. 
  • Immune response of chimpanzee to purified melanoma 250 kilodalton tumor-associated antigen. 
  • Immune responses of breast cancer patients to mutated epidermal growth factor receptor (EGF-RvIII, Delta EGF-R, and de2-7 EGF-R). 
  • Immunocompetent T-cells with a memory-like phenotype are the dominant cell type following antibody-mediated T-cell depletion. 
  • Immunologic control of the ascites of murine adenocarcinoma 755. I. Protection with syngeneic immune serum or lymphoid cells. 
  • Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. 
  • Immunotherapy of murine leukemia. II. Effect of passive serum therapy on Friend murine leukemia virus-induced hematologic and coagulation parameters. 
  • In vivo and in vitro binding of iodinated monoclonal antibody A2B5 to RIN insulinoma cells. 
  • In vivo tumor localization using tumor-specific monkey xenoantibody, alloantibody, and murine monoclonal xenoantibody. 
  • Inefficient dystrophin expression after cord blood transplantation in Duchenne muscular dystrophy. 
  • Infections after the use of alemtuzumab in solid organ transplant recipients: a comparative study. 
  • Inhibition of NF-kappaB1 and NF-kappaB2 activation in prostate cancer cells treated with antibody against the carboxyl terminal domain of GRP78: effect of p53 upregulation. 
  • Inhibition of the growth of human melanoma metastases in nude mice by melanoma-specific murine monoclonal antibody. 
  • Intralesional BCG, intravenous immune lymphocytes, and immunization with neuraminidase-treated tumor cells to manage melanoma; A clinical assessment. 
  • Lymphocytic lymphoma and systemic lupus erythematosus: their coexistence with antibody to the Sm antigen. 
  • Molecular and immunological analysis of genetic prostate specific antigen (PSA) vaccine. 
  • Monoclonal antibodies as targeted therapy in hematologic malignancies in older adults. 
  • Mouse/human chimeric Me1-14 antibody: genomic cloning of the variable region genes, linkage to human constant region genes, expression, and characterization. 
  • Multiple assay characterization of murine monoclonal antimelanoma antibodies. 
  • Obesity following kidney transplantation and steroid avoidance immunosuppression. 
  • Occult malignancy in patients with suspected paraneoplastic neurologic syndromes: value of positron emission tomography in diagnosis. 
  • Outcomes at 3 years of a prospective pilot study of Campath-1H and sirolimus immunosuppression for renal transplantation. 
  • PFT-alpha inhibits antibody-induced activation of p53 and pro-apoptotic signaling in 1-LN prostate cancer cells. 
  • Pharmacokinetic analysis of the perivascular distribution of bifunctional antibodies and haptens: comparison with experimental data. 
  • Positive relationship of clinical and serologic responses to vaccinia melanoma oncolysate. 
  • Posttransplant lymphoproliferative disorder following nonmyeloablative allogeneic stem cell transplantation. 
  • Present experience with Campath-1H in organ transplantation and its potential use in pediatric recipients. 
  • Production and characterization of two human glioma xenograft-localizing monoclonal antibodies. 
  • Progressive multifocal leukoencephalopathy following heightened immunosuppression after lung transplant. 
  • Prospects for the immunological management of lethal tumors. 
  • Proteomics for monitoring immune responses to cancer vaccines. 
  • Relevance for neurobiology and neurooncology of antigens of malignant gliomas as defined by monoclonal antibodies. 
  • Results from a human renal allograft tolerance trial evaluating T-cell depletion with alemtuzumab combined with deoxyspergualin. 
  • Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H). 
  • Results of a phase 1 study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children and young adults with brain cancer. 
  • Sequential adsorption analysis of antibodies to neuroectodermal cells by an indirect quantitative method. 
  • Specific cytotoxic antibody in the sera of patients with melanoma. 
  • Staging non-small cell carcinoma of the lung using technetium-99m-labeled monoclonal antibodies. 
  • Stem cell transplantation for multiple myeloma. 
  • Successful tumour immunotherapy: possible role of antibodies to anti-inflammatory factors produced by neoplasms. 
  • Surface antigenic characteristics of human glial brain tumor cells. 
  • Surface antigens of human glioma cells shared with normal adult and fetal brain. 
  • Synthesis of radioiodinated N-succinimidyl iodobenzoate: optimization for use in antibody labelling. 
  • T-lymphocyte alloresponses of Campath-1H-treated kidney transplant patients. 
  • The Escherichia coli subtilase cytotoxin A subunit specifically cleaves cell-surface GRP78 protein and abolishes COOH-terminal-dependent signaling. 
  • The evolving role of alemtuzumab (Campath-1H) for immunosuppressive therapy in organ transplantation. 
  • The role of alemtuzumab in facilitating maintenance immunosuppression minimization following solid organ transplantation. 
  • The use of non-human primates for production of antisera to human tumor-associated antigens. 
  • Transplantation of high panel-reactive antibody left ventricular assist device patients without crossmatch using on-bypass pheresis and alemtuzumab. 
  • Treatment of refractory acute rejection in a lung transplant recipient with campath 1H. 
  • Treatment options for newly diagnosed patients with chronic lymphocytic leukemia. 
  • Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors. 
• 

  Keywords of People

  • Berchuck, Andrew, James M. Ingram Distinguished Professor of Gynecologic Oncology, Obstetrics and Gynecology, Gynecologic Oncology
  • Pitt, Geoffrey Stuart, Adjunct Professor in the Department of Medicine, Medicine, Cardiology
  • Sampson, John Howard, Robert H., M.D. and Gloria Wilkins Professor of Neurosurgery, in the School of Medicine, Biomedical Engineering